Aflibercept: Eylea and 1 biosimilar

1 biosimilar bill against Eylea (J0178). On average they are paid ↑ 5.7% relative to the reference product per 1 MG in 4Q26.

Eylea (reference)
Pavblu

Payment limit per 1 MG, last 8 quarters. Reference product as the thick navy line, biosimilars in teal and other colors.

All products

Product	Code	CMS description	Per 1 MG	vs. reference	CMS 8% add-on note	8 quarters
Eylea	J0178	Aflibercept injection	$722.251	Reference	–
Pavblu	Q5147	Inj, aflibercept-ayyh, 1 mg	$763.376	↑ 5.7%	No

Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.